Email updates

Keep up to date with the latest news and content from BMC Veterinary Research and BioMed Central.

Open Access Highly Accessed Research article

Emergency vaccination alleviates highly pathogenic porcine reproductive and respiratory syndrome virus infection after contact exposure

Xiao Li1, Li Qiu2, Zengqi Yang2*, Ruiyi Dang2 and Xinglong Wang2*

Author affiliations

1 College of Animal Science and Technology, Northwest A&F University, Yangling, 712100, China

2 College of Veterinary Medicine, Northwest A&F University, Yangling, 712100, China

For all author emails, please log on.

Citation and License

BMC Veterinary Research 2013, 9:26  doi:10.1186/1746-6148-9-26

Published: 9 February 2013

Abstract

Background

To assess the effectiveness of emergency vaccination for reducing the contact-induced infection and pathological damage caused by the highly pathogenic porcine reproductive and respiratory syndrome virus (HPPRRSV), Twenty pigs were equally divided into four groups. Groups 1, 2 and 3 were housed in one unit, whereas Group 4 was separately housed. Group 1 was challenged with HPPRRSV on day 0. Group 2 and 4 did not receive treatment and were used as the contact-infected and uninfected controls, respectively. Group 3 was treated with the attenuated vaccine at 0 days post-inoculation. The rectal temperatures, clinical signs, pathologic lesions and viraemia of the piglets were detected and evaluated.

Results

The vaccinated pigs in Group 3 showed less clinical morbidity, viraemia, temperature fluctuations and lung lesions at 14 days post-inoculation, as compared with the contact-infected (Group 2) and experimentally infected (Group 1) pigs. Higher serum IFN-γ levels were detected among the pigs that received emergency immunisation. Thus, IFN-γ may be involved in immunity against HPPRRSV infection.

Conclusions

These results indicated that emergency vaccination could effectively alleviate HPPRRSV infection during experimental contact exposure. Our findings provide a novel and useful strategy for controlling clinical HPPRRSV.